Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire acquires Methypatch

Executive Summary

Shire acquires worldwide sales & marketing rights to the pending attention deficit and hyperactivity disorder treatment Methypatch from Noven. The company expects future Methypatch (methylphenidate transdermal) sales to offset generic erosion of Adderall (amphetamine). Barr's ANDA for Adderall was approved Feb. 11 (1"The Pink Sheet" Feb. 10, p. 29). "Shire will make an upfront payment to Noven of $25 mil. followed by separate milestone payments up to $125 mil., which will be dependent on FDA approval and the achievement of certain sales targets," company said. Methypatch has an estimated user fee goal of June 2003...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS041371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel